Influence of impaired T- and B-cell compartments on efficacy of IVIg in dysimmune neuropathies.
Autoimmune mechanisms are postulated to play a role in the development and progression of dysimmune neuropathies (DN). We investigated the relation between lymphocyte number and marker expression, and disease activity in 20 patients with DN under intravenous immunoglobulins (IVIg) treatment. B- and T-lymphocyte markers were studied by flow cytometry of the expression of CD5, CD25, CD23 and CD38 markers on B cells and of CD3, CD4 and CD8 markers, respectively. These parameters were compared with those obtained from matched healthy volunteers. The proportions of CD38+ B cells were higher in patients compared with those of controls. Proportions of activated CD4+ and CD8+ T cells were comparable in peripheral blood mononuclear cells of patients and controls, but a significant reduction of the absolute numbers of CD3+, CD4+ and CD8+ cells were observed in DN patients. The percentages of CD25+ memory T cells were instead significantly increased in DN patients. Lastly, T-cell reduction and the CD19/CD38 ratio over total B (CD19+) cells directly correlated with a poor response to IVIg therapy. In DN, whereas T-cell number is reduced, activated T and B cells are increased, thus suggesting an intrinsic defect of the immune response.
Matà
S
S
Department of Neurological and Psychiatric Sciences, Section of Immunoallergology and Respiratory Disease, University of Firenze, Firenze, Italy. masa@unifi.it
Corzani
S
S
Biagiotti
R
R
Piacentini
S
S
Siracusa
G
G
Giudizi
M G
MG
Mastio
M D
MD
Borsini
W
W
Taiuti
R
R
Vultaggio
A
A
Sorbi
S
S
Maggi
E
E
D000328:Adult; D000368:Aged; D016175:B-Lymphocyte Subsets / Q000378:metabolism / Q000473:pathology*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D011129:Polyradiculoneuropathy / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000378:metabolism / Q000473:pathology*
D015415:Biomarkers; D016756:Immunoglobulins, Intravenous